Clinical trials: Acne Lesions
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Acne, Scars
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne.
- Trial name
- NCT04806594
- Testing
- Papix acne scar
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Relife S.r.l.
Acne
Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects
The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57…
- Trial name
- NCT05168397
- Testing
- RV4857A
- Where
- Portugal
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with…
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211497
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 255 people
- Sponsor
- BioWest Therapeutics Inc
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Acne Vulgaris
Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, double-blinded, vehicle-controlled, parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GI148512 (benzoyl peroxide [BPO] 3% gel) when applied once daily…
- Trial name
- NCT01400932
- Testing
- GI148512, vehicle gel
- Where
- 19 sites in Japan
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
Hair Reduction, Tattoo Removal
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
This is a non-randomized, multi-center, open-label, prospective clinical study evaluating the clinical treatment with Candela Medical Technology.
- Conditions
- Hair Reduction, Tattoo Removal, Wrinkle, Acne
- Trial name
- NCT06202274
- Testing
- Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
- Where
- 3 sites in United States, Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Skin Diseases
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
5 Day study to assess how quickly a topical acne product begins to work.
- Trial name
- NCT02052752
- Testing
- 3% Benzoyl Peroxide, Neutrogena Rapid Clear®
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic
AV-23-001 AVAVA MIRIA Pilot Study
This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to…
- Conditions
- Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity
- Trial name
- NCT06557434
- Testing
- MIRIA
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Acne Vulgaris
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory…
- Trial name
- NCT01320033
- Testing
- CD2475/101 40 mg, Doxycycline 100 mg
- Where
- 31 sites in United States
- Volunteers
- 662 people
- Sponsor
- Galderma R&D
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211523
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 75 people
- Sponsor
- BioWest Therapeutics Inc
Excessive Hairiness, Vascular Lesion
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias.
- Conditions
- Excessive Hairiness, Vascular Lesion, Pigmented Lesions, Acne Vulgaris
- Trial name
- Anthelia (NCT06655129)
- Testing
- intense pulsed light
- Where
- 5 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eurofeedback
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
AVAVA MIRIA General Use
A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment.
- Conditions
- Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle
- Trial name
- NCT06868615
- Testing
- AVAVA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Acne, Healthy
Assessment of Biological, Biometrological Parameters and Consumer Needs in Adult Subjects with Acne
Acne vulgaris (acne) is a chronic inflammatory pathology of the pilosebaceous unit. Its prevalence is about 85% of teenagers and is constantly increasing in adults, especially women.
- Trial name
- NCT06841393
- Testing
- Biometrological measurements, Biological sampling, Clinical assessments
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Acne, Acne Vulgaris
Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions
Artificial intelligence (AI) based on imaging holds tremendous potential to enhance visual diagnostic accuracy in the medical field.
- Conditions
- Acne, Acne Vulgaris, Alopecia, Androgenetic, Pigmented Lesions
- Trial name
- IDEI_2023 (NCT06263413)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- AI Labs Group S.L
Acne
Evaluation of Effaclar Duo+M on Acne Lesions in Subjects With Mild to Moderate Acne on Face and Trunk
This single-center, open, non-randomized study aims the efficacy evaluation of Effaclar Duo+M and Effaclar+M Purifying foaming gel on total acne lesion count, pigmented lesions and scars for 6 months in subjects with mild to…
- Trial name
- NCT06463925
- Testing
- acneic participants group
- Where
- Brazil
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Pseudofolliculitis Barbae, Unwanted Hair
Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus
Demonstrate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended uses: hair removal including pseudofolliculitis barbae (PFB), clearance of pigmented and/or vascular lesions, temporary increase of…
- Conditions
- Pseudofolliculitis Barbae, Unwanted Hair, Pigmented Lesions, Vascular Lesion
- Trial name
- NCT04993066
- Testing
- GentleMax Pro Plus
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Wrinkle, Acne Scars
Post Market Usability Evaluation Of The PicoSure Pro Device
The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.
- Conditions
- Wrinkle, Acne Scars, Benign Epidermal Pigmented Lesions, Benign Dermal Pigmented Lesions
- Trial name
- NCT05102617
- Testing
- PicoSure Pro Device, PicoSure Device, Topical Cosmeceuticals
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cynosure, Inc.